CervoMed Q2 2024 EPS $(0.27) Beats $(0.42) Estimate, Sales $3.29M Beat $2.08M Estimate
Portfolio Pulse from Benzinga Newsdesk
CervoMed (NASDAQ:CRVO) reported better-than-expected Q2 2024 results with an EPS of $(0.27) beating the estimate of $(0.42) and sales of $3.29 million surpassing the $2.08 million estimate.
August 12, 2024 | 12:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CervoMed reported Q2 2024 EPS of $(0.27), beating the $(0.42) estimate, and sales of $3.29M, surpassing the $2.08M estimate.
CervoMed's better-than-expected EPS and sales figures are likely to positively impact its stock price in the short term as they indicate stronger financial performance than anticipated.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100